July 7 (Reuters) - The Nasdaq was set to open lower on Tuesday amid declining chip stocks, with investors questioning the momentum of the AI-led rally despite Samsung's strong earnings, while a report on China's DeepSeek making its own AI chip also hit sentiment. .N

** Tesla Inc TSLA.O:
BUZZ - RBC lifts Tesla price target, cites potential SpaceX deal nL6N4390FS

** Space Exploration Technologies Corp SPCX.O:
BUZZ - Down ahead of Nasdaq 100 inclusion, brokerages start coverage nL4N4390M7

** Rivian Automotive Inc RIVN.O:
BUZZ - Falls after announcing stock offering nL6N4390KK

** Sandisk Corp SNDK.O:

** Seagate Technology Holdings PLC STX.O:

** Western Digital Corp WDC.O:

BUZZ - US chip stocks falls after Samsung results spark fresh AI jitters nL4N4390P9

** Cloudflare Inc NET.N:
BUZZ - Gains; Scotiabank raises to 'sector outperform' nL6N4390LK

** Crinetics Pharmaceuticals Inc CRNX.O:
BUZZ - Soars as Vertex agrees to $10 billion buyout nL4N4390T7

** Agios Pharmaceuticals Inc AGIO.O:
BUZZ - Rises as FDA grants priority review to sickle cell disease drug nL4N4390VL

** Compass Pathways PLC CMPS.O:
BUZZ - Rises on positive late-stage trial data for depression drug nL4N4390VB

** Nvidia Corp NVDA.O:
BUZZ - Falls after report DeepSeek developing its own AI chip nL4N4390V2

** Plug Power Inc PLUG.O:
BUZZ - Rises as Australia hydrogen project reaches FID nL4N4390WXx

** Kailera Therapeutics Inc KLRA.O:
BUZZ - Up after weight-loss drug meets main goal of late-stage trials in China nL4N4390VP

** MeiraGTx Holdings Inc MGTX.O:
BUZZ - Rises as Oberland Capital commits up to $400 mln for late-stage gene therapies nL4N4390Y2

** Tvardi Therapeutics Inc TVRD.O:
BUZZ - Rises as oral inflammation drug shows early-stage trial promise nL4N4390Z8

** Vivani Medical Inc VANI.O:
BUZZ - Jumps as Novo Nordisk evaluates weight-loss drug implant nL4N4390ZM

** Expedia Group Inc EXPE.O:
BUZZ - Argus Research raises Expedia's PT on strong growth outlook nL4N4390ZQ

** Amrize AG AMRZ.N:
BUZZ - Falls after Truist downgrades to 'hold', cuts PT nL4N43910F

** Revolution Medicines Inc RVMD.O:
BUZZ - Rises as EU regulator starts phased review of cancer drug nL4N43914J